Description

BSE notifies listing of 31,75,000 new equity shares of Concord Drugs Limited on preferential basis, effective April 21, 2026, with lock-in periods until October 2026 and October 2027.

Summary

BSE has notified trading members that 31,75,000 new equity shares of Concord Drugs Limited (Scrip Code: 538965) are listed and permitted to trade on the Exchange effective Tuesday, April 21, 2026. The shares were issued on a preferential basis to Promoter and Non-Promoter entities at an issue price of Rs. 36.30 per share (face value Rs. 10 + premium Rs. 26.30).

Key Points

  • 31,75,000 equity shares of Rs. 10/- each issued at a premium of Rs. 26.30/- on a preferential basis
  • Issue price: Rs. 36.30/- per share
  • ISIN: INE858L01010
  • Date of allotment: 20 November 2025
  • New shares rank pari-passu with existing equity shares
  • Distribution numbers: 10000001 to 13175000
  • Trading effective from April 21, 2026

Regulatory Changes

No new regulatory changes. This is a standard listing notice under BSE’s Listing Operations for newly allotted preferential shares.

Compliance Requirements

  • Trading members must note the lock-in restrictions before executing trades in the newly listed shares
  • Shares under lock-in cannot be sold until the respective lock-in expiry dates

Important Dates

  • Date of Allotment: 20 November 2025
  • Listing / Trading Commencement: 21 April 2026
  • Lock-in Expiry (5,00,000 shares | Dist. Nos. 10000001–10500000): 30 October 2027
  • Lock-in Expiry (26,75,000 shares | Dist. Nos. 10500001–13175000): 30 October 2026

Impact Assessment

The listing adds 31,75,000 shares to the tradable float of Concord Drugs Limited, though most shares (26,75,000) remain under lock-in until October 2026 and a smaller tranche (5,00,000) until October 2027. Immediate free-float impact is minimal given the lock-in constraints. The preferential allotment at Rs. 36.30 signals promoter and investor confidence at that price point. Market impact is limited to existing shareholders and traders in Scrip Code 538965.

Impact Justification

Routine preferential allotment listing for a small-cap company; limited broader market impact, affects only existing and prospective shareholders of Concord Drugs Limited.